PAPER Kitamura Y, Shimohama S, Kamoshima W, Matsuoka Y, Nomura Y, Taniguchi T

Changes of p53 in the brains of patients with Alzheimer's disease.

Biochem Biophys Res Commun. 1997 Mar 17;232(2):418-21. PubMed: 9125193

PAPER Atanasoski S, Boentert M, De Ventura L, Pohl H, Baranek C, Beier K, Young P, Barbacid M, Suter U

Postnatal Schwann cell proliferation but not myelination is strictly and uniquely dependent on cyclin-dependent kinase 4 (cdk4).

Mol Cell Neurosci. 2008 Mar;37(3):519-27. PubMed: 18191580

PAPER Puyol M, Martín A, Dubus P, Mulero F, Pizcueta P, Khan G, Guerra C, Santamaría D, Barbacid M

A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma.

Cancer Cell. 2010 Jul 13;18(1):63-73. PubMed: 20609353

PAPER Rane SG, Dubus P, Mettus RV, Galbreath EJ, Boden G, Reddy EP, Barbacid M

Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in beta-islet cell hyperplasia.

Nat Genet. 1999 May;22(1):44-52. PubMed: 10319860

PAPER Santamaría D, Barrière C, Cerqueira A, Hunt S, Tardy C, Newton K, Cáceres JF, Dubus P, Malumbres M, Barbacid M

Cdk1 is sufficient to drive the mammalian cell cycle.

Nature. 2007 Aug 16;448(7155):811-5. PubMed: 17700700

Patrick Mallory

None
Loveland, United States

Ipsen Colloquium on Alzheimer's Disease 2010

CONFERENCE COVERAGE SERIES Two Faces of Evil: Cancer and Neurodegeneration Ipsen Colloquium on Alzheimer's Disease

Bharathi Gadad on PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease.

COMMENT I strongly recommend the paper. It’s really interesting to know that PGC-1α slows down the progression of the disease. The authors have focused on an important aspect which might be an appealing target for drugs and also help to detect PD symptoms at an e

PAPER Zheng B, Liao Z, Locascio JJ, Lesniak KA, Roderick SS, Watt ML, Eklund AC, Zhang-James Y, Kim PD, Hauser MA, Grünblatt E, Moran LB, Mandel SA, Riederer P, Miller RM, Federoff HJ, Wüllner U, Papapetropoulos S, Youdim MB, Cantuti-Castelvetri I, Young AB, Vance JM, Davis RL, Hedreen JC, Adler CH, Beach TG, Graeber MB, Middleton FA, Rochet JC, Scherzer CR,

PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease.

Sci Transl Med. 2010 Oct 6;2(52):52ra73. PubMed: 20926834

Sam Gandy on Retrieval of the Alzheimer's amyloid precursor protein from the endosome to the TGN is S655 phosphorylation state-dependent and retromer-mediated.

COMMENT The narrative on APP phosphorylation began in 1988 with the discovery that threonine 654 and serine 655 were potentially phospho-acceptor sites for protein kinase C (PKC) and Ca2+/calmodulin-dependent protein kinase II (CaMKII) (Gandy et al., 1988). Based

Judith Jaeger

AstraZeneca
United States

PAPER Hung AY, Haass C, Nitsch RM, Qiu WQ, Citron M, Wurtman RJ, Growdon JH, Selkoe DJ

Activation of protein kinase C inhibits cellular production of the amyloid beta-protein.

J Biol Chem. 1993 Nov 5;268(31):22959-62. PubMed: 8226807

PAPER da Cruz E Silva OA, Iverfeldt K, Oltersdorf T, Sinha S, Lieberburg I, Ramabhadran TV, Suzuki T, Sisodia SS, Gandy S, Greengard P

Regulated cleavage of Alzheimer beta-amyloid precursor protein in the absence of the cytoplasmic tail.

Neuroscience. 1993 Dec;57(4):873-7. PubMed: 8309547

PAPER Vieira SI, Rebelo S, Esselmann H, Wiltfang J, Lah J, Lane R, Small SA, Gandy S, da Cruz E Silva EF, da Cruz E Silva OA

Retrieval of the Alzheimer's amyloid precursor protein from the endosome to the TGN is S655 phosphorylation state-dependent and retromer-mediated.

Mol Neurodegener. 2010;5:40. PubMed: 20937087

Alan Weids